OneSource Specialty Pharma, a leading Contract Development and Manufacturing Organisation (CDMO) and associate company of Strides, has entered into a strategic licensing agreement with Bhami’s Research Laboratory (BRL), a move poised to revolutionize the delivery of high-concentration biologic therapies. This collaboration grants OneSource access to BRL’s cutting-edge HILOPRO formulation technology, designed to facilitate the subcutaneous administration of biologics by reducing their viscosity, which is particularly advantageous for monoclonal antibodies and fusion proteins.
The HILOPRO technology is a significant breakthrough as it addresses a critical challenge in biologic drug delivery. Biologic therapies, often administered intravenously, can be cumbersome and costly due to the need for hospital stays and professional administration. The innovative HILOPRO formulation allows these therapies to be delivered subcutaneously, which means patients can receive treatments via a simpler, less invasive method. This change not only enhances patient comfort and compliance but also reduces healthcare costs and hospital dependency.
Neeraj Sharma, Managing Director of OneSource, expressed enthusiasm about the partnership with BRL. He highlighted that this collaboration marks a significant advancement for OneSource, enhancing their capabilities in the subcutaneous delivery of biologic therapies. Sharma emphasized the benefits of subcutaneous delivery for small-volume, low-viscosity biotherapeutics, which include improved healthcare accessibility, reduced hospitalisation, and lower overall treatment costs. These advantages are expected to make a substantial difference in patient care and treatment efficiency.
Dr. Surya Pai, Co-founder and Chief Executive Officer of BRL, also commented on the partnership, underscoring the importance of this advancement in biologic therapy delivery. He noted that BRL’s globally patented high-concentration, low-viscosity protein drug delivery platform aims to optimize patient care by offering convenient, affordable, and safe treatment options. Dr. Pai expressed confidence that the partnership with OneSource would set new benchmarks in biopharmaceutical innovation and significantly improve healthcare outcomes worldwide.
The agreement between OneSource and BRL signifies a strategic alignment to push the boundaries of biopharmaceutical development. By integrating BRL’s HILOPRO technology, OneSource will enhance its development and manufacturing services for both drug products and substances. This synergy is expected to drive innovation in biologic drug formulations and pave the way for more efficient and patient-friendly therapeutic options.
In summary, the strategic licensing agreement between OneSource Specialty Pharma and Bhami’s Research Laboratory represents a pivotal moment in the field of biologic therapies. The adoption of the HILOPRO formulation technology for subcutaneous delivery of high-concentration biologics promises to transform patient care by making treatments more accessible, less invasive, and more cost-effective. This partnership underscores both companies’ commitment to advancing healthcare through innovative solutions, setting the stage for improved patient outcomes and healthcare delivery standards globally.
SOURCE:
ECONOMIC TIMES
